Claims
- 1. A vaccine comprising a delivery vehicle in combination with a sterol for immunizing or hyperimmunizing a human against the sterol.
- 2. The vaccine of claim 1, wherein the delivery vehicle is selected from the group consisting of biocompatible-biodegradable polymers, biocompatible-nonbiodegradable polymers, liposomes, lipospheres, slow release devices and combinations thereof.
- 3. The vaccine of claim 1, wherein the delivery vehicle is a liposome.
- 4. The vaccine of claim 3, wherein the liposome contains a lipid selected from the group consisting of phosphatidyl choline and dimyristoyl phosphatidyl choline.
- 5. The vaccine of claim 4, wherein the liposome contains phosphatidyl choline.
- 6. The vaccine of claim 4, wherein the liposome contains dimyristoyl phosphatidyl choline.
- 7. The vaccine of claim 1, further comprising an adjuvant.
- 8. The vaccine of claim 7, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide. aluminum phosphate, and lipid A.
- 9. The vaccine of claim 8, wherein the adjuvant is lipid A.
- 10. The vaccine of claim 3 further comprising an adjuvant.
- 11. The vaccine of claim 10, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, and lipid A.
- 12. The vaccine of claim 11, wherein the adjuvant is lipid A.
- 13. The vaccine of claim 1, wherein the sterol is cholesterol or a derivative thereof.
- 14. The vaccine of claim 13, wherein the sterol is phosphatidylcholesterol.
- 15. The vaccine of claim 13, wherein the sterol is cholesterol ester.
- 16. The vaccine of claim 13, wherein the delivery vehicle is a liposome.
- 17. The vaccine of claim 16, wherein the liposome contains a lipid selected from the group consisting of phosphatidyl choline and dimyristoyl phosphatidyl choline.
- 18. The vaccine of claim 17, wherein the liposome contains phosphatidyl choline.
- 19. The vaccine of claim 17, wherein the liposome contains dimyristoyl phosphatidyl choline.
- 20. The vaccine of claim 13, further comprising an adjuvant.
- 21. The vaccine of claim 20, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, and lipid A.
- 22. The vaccine of claim 21, wherein the adjuvant is lipid A.
- 23. The vaccine of claim 1, wherein the sterol is ergosterol or a derivative thereof.
- 24. The vaccine of claim 23, wherein the delivery vehicle is a liposome.
- 25. The vaccine of claim 24, wherein the liposome contains a lipid selected from the group consisting of phosphatidyl choline and dimyristoyl phosphatidyl choline.
- 26. The vaccine of claim 25, wherein the liposome contains phosphatidyl choline.
- 27. The vaccine of claim 25, wherein the liposome contains dimyristoyl phosphatidyl choline.
- 28. The vaccine of claim 23, further comprising an adjuvant.
- 29. The vaccine of claim 28, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, and lipid A.
- 30. The vaccine of claim 29, wherein the adjuvant is lipid A.
- 31. A therapeutic method for vaccinating a human against cholesterol to treat or prevent hypercholesterolemia or atherosclerosis comprising, administering to a human an amount effective to immunize the individual against cholesterol of a vaccine comprising a delivery vehicle and cholesterol or a derivative thereof.
- 32. The method of claim 31, wherein the delivery vehicle is a liposome.
- 33. The method of claim 32, wherein the liposome contains a lipid selected from the group consisting of phosphatidyl choline and dimyristoyl phosphatidyl choline.
- 34. The method of claim 33, wherein the liposome contains phosphatidyl choline.
- 35. The method of claim 33, wherein the liposome contains dimyristoyl phosphatidyl choline.
- 36. The method of claim 31, wherein the vaccine further comprises an adjuvant.
- 37. The method of claim 36, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide. aluminum phosphate, and lipid A.
- 38. The method of claim 37, wherein the adjuvant is lipid A.
- 39. The method of claim 31, wherein the cholesterol derivative is phosphatidylcholesterol.
- 40. The method of claim 31, wherein the cholesterol derivative is cholesterol ester.
- 41. A therapeutic method for vaccinating a human or animal against ergosterol to treat or prevent fungal infection comprising, administering to a human or animal with a fungal infection an amount effective to immunize the human or animal against ergosterol comprising a delivery vehicle and ergosterol or derivatives thereof.
- 42. The method of claim 41, wherein the deliver vehicle is a liposome.
- 43. The method of claim 42, wherein the liposome contains a lipid selected from the group consisting of phosphatidyl choline and dimyristoyl phosphatidyl choline.
- 44. The method of claim 43, wherein the liposome contains phosphatidyl choline.
- 45. The method of claim 43, wherein the liposome contains dimyristoyl phosphatidyl choline.
- 46. The method of claim 41, where the vaccine further comprises an adjuvant.
- 47. The method of claim 46, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, and lipid A.
- 48. The method of claim 47, wherein the adjuvant is lipid A.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of U.S. patent application Ser. No. 07/997,954, filed Dec. 29, 1992, which is a continuation-in-part of U.S. patent application Ser. No. 07/624,957, filed Dec. 10, 1990.
GOVERNMENT INTEREST
[0002] The United States Government may have certain interests in the inventions described herein.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09023256 |
Feb 1998 |
US |
Child |
09846776 |
May 2001 |
US |
Parent |
08422633 |
Apr 1995 |
US |
Child |
09023256 |
Feb 1998 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
07997954 |
Dec 1992 |
US |
Child |
08422633 |
Apr 1995 |
US |
Parent |
07624957 |
Dec 1990 |
US |
Child |
07997954 |
Dec 1992 |
US |